Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Synflutide HFA vs Seretide Evohaler in Healthy Volunteers
NCT02466347Phase 1Completed
- Sponsor
- Intech Biopharm Corporation
- Start
- Jun 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Synflutide HFA 250/25 Inhaler in asthma and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Intech Biopharm Corporation. Primary endpoints: Area Under Curve at 24 hours and Maximum plasma concentration at 24 hours. Started Jun 2014; status: completed.
02
Drugs
Synflutide HFA 250/25 Inhaler
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02466347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02466347.